fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Bromazepam

All products: not a benefit

Lectopam · DIN 00518131 · 6 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-31 — choose a marketed DIN from the same-category list.Discontinued March 31, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-03-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-03-31 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Lectopam · DIN 00518131 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-03-31 · brand LECTOPAM TAB 6MG · ATC N05BA08 BROMAZEPAM · form Tablet · route Oral · ingredients BROMAZEPAM 6 MG · company Hoffmann-la roche limited · schedule Targeted substances (cdsa iv)
Re-check Health Canada status and shortages (live) · Health Canada product record

Lectopam: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00518131)

Source record
DIN 00518131: Lectopam Raw flags: notABenefit=Y, sec3=Y Item: 281608122; group id 481; item number 1226; lccId None; manufacturer id HLR Source form: Tab; strength: 6mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00518131 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4158
Interchangeable products
Apo-Bromazepam · DIN 02177188 · $0.1310 Teva-Bromazepam · DIN 02230585 · $0.1310
Shortage status: discontinued (March 31, 2018, reported by HOFFMANN-LA ROCHE LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00518131
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since March 31, 2018 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N05BA): coverage varies; not interchangeable

  • Alprazolam (Xanax): general benefit, not a benefit
  • Chlordiazepoxide (Librium): general benefit, not a benefit
  • Clorazepate dipotassium (Tranxene): general benefit, not a benefit
  • Diazepam (Diazepam Injection USP): general benefit, limited Use 481, not a benefit
  • Lorazepam (Apo-Lorazepam): general benefit, not a benefit
  • Oxazepam (Apo-Oxazepam): general benefit, not a benefit

1 more in the class list below

Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ALPRAZOLAM

· 12 products · General benefit (6), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 0.25mg, 0.5mg, 1mg, 2mg · Tab

CHLORDIAZEPOXIDE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 25mg · Cap

CLORAZEPATE DIPOTASSIUM

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 3.75mg, 7.5mg, 15mg · Cap

DIAZEPAM

· 10 products · Limited Use, codes 481 (1), General benefit (6), Listed, not a benefit (3) · strengths: 5mg/mL, 10mg/2mL, 15mg/3mL, 2mg, 5mg, 10mg · Inj Sol (Preservative Free), Rect Gel-2x 5mg Pk, Rect Gel-2x10mg Pk, Rect Gel-2x15mg Pk, Tab

LORAZEPAM

· 12 products · General benefit (9), Listed, not a benefit (3) · strengths: 0.5mg, 1mg, 2mg · Tab

OXAZEPAM

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 10mg, 15mg, 30mg · Tab

HYDROXYZINE HCL

· 8 products · Listed, not a benefit · strengths: 10mg, 25mg, 50mg · Cap

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-BROMAZEPAM (bromazepam) is useful for the short-term, symptomatic relief of manifestations of excessive anxiety in patients with anxiety neurosis. Geriatrics: Long-term use of APO-BROMAZEPAM should be avoided in elderly patients. Enhanced monitoring is recommended (see WARNINGS AND PRECAUTIONS, Falls and fractures; DOSAGE AND ADMINISTRATION, Dosing considerations). Pediatrics: APO-BROMAZEPAM is not recommended for children under 18 years of age (see WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). Page 3 of 28 https://pdf.hres.ca/dpd_pm/00067862.PDF PM date: OCT 18, 2022 Source product: APO-BROMAZEPAM; DIN 02177161; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Lectopam · DIN 00518131 Shortage status: discontinued (2018-03-31, reported by HOFFMANN-LA ROCHE LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00518131

Check this DIN again

Other review policies

For Lectopam: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026